Torren Management’s Axsome Therapeutics AXSM Stock Holding History

Torren Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-28	Closed	-$5.11K	–	1038
2025 Q4	$5.11K	Buy	+28	New	+$3.91K	﹤0.01%	903

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Torren Management's AXSM Position: Q1 2026 in Review

Torren Management sold out of Axsome Therapeutics (AXSM) in Q1 2026, closing a stake of 28 shares — an estimated $5.11K sold.

Torren Management first reported a position in AXSM in Q4 2025 and held it in 1 quarter. The position peaked at $5.11K in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Torren Management reported no remaining Axsome Therapeutics position as of Q1 2026 after selling out during the quarter.
Torren Management sold 28 Axsome Therapeutics shares in Q1 2026, an estimated $5.11K.
Torren Management first reported a position in Axsome Therapeutics in Q4 2025 and held it in 1 quarter.
Torren Management's Axsome Therapeutics position peaked at $5.11K in Q4 2025.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Torren Management's 13F filing for Q1 2026, filed 30 Apr 2026.